Journal: Nature reviews. Cancer
This review highlights recent advances in antibody-drug conjugates (ADCs), including their increasing clinical approvals, earlier use in treatment lines, and combination with immunotherapies.
It emphasizes the complexity of ADC design, focusing on how molecular components affect:
- Distribution
- Efficacy
- Toxicity
The article also explores the immunological effects of ADCs, such as:
- Immunogenic cell death
- Dendritic cell activation
- Antibody-Fc interactions
These mechanisms enhance therapeutic effects beyond direct cytotoxicity.
Overall, these insights aim to guide the development of improved ADCs and rational combination strategies in oncology.